Cargando…

Gastric adenocarcinoma burden, trends and survival in Cali, Colombia: A retrospective cohort study

BACKGROUND: Gastric adenocarcinoma (GA) has changed in recent decades. Cancer estimates are often calculated from population-based cancer registries, which lack valuable information to guide decision-making (clinical outcomes). We describe the trends in clinical practice for GA using a hospital-base...

Descripción completa

Detalles Bibliográficos
Autores principales: Parra-Lara, Luis Gabriel, Falla-Martínez, Juan Camilo, Isaza-Pierotti, Daniel Francisco, Mendoza-Urbano, Diana Marcela, Tangua-Arias, Andrés R., Bravo, Juan Carlos, Bravo, Luis Eduardo, Zambrano, Ángela R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028196/
https://www.ncbi.nlm.nih.gov/pubmed/36959805
http://dx.doi.org/10.3389/fonc.2023.1069369
_version_ 1784909893210210304
author Parra-Lara, Luis Gabriel
Falla-Martínez, Juan Camilo
Isaza-Pierotti, Daniel Francisco
Mendoza-Urbano, Diana Marcela
Tangua-Arias, Andrés R.
Bravo, Juan Carlos
Bravo, Luis Eduardo
Zambrano, Ángela R.
author_facet Parra-Lara, Luis Gabriel
Falla-Martínez, Juan Camilo
Isaza-Pierotti, Daniel Francisco
Mendoza-Urbano, Diana Marcela
Tangua-Arias, Andrés R.
Bravo, Juan Carlos
Bravo, Luis Eduardo
Zambrano, Ángela R.
author_sort Parra-Lara, Luis Gabriel
collection PubMed
description BACKGROUND: Gastric adenocarcinoma (GA) has changed in recent decades. Cancer estimates are often calculated from population-based cancer registries, which lack valuable information to guide decision-making (clinical outcomes). We describe the trends in clinical practice for GA using a hospital-based cancer registry over a timespan of 15 years. METHODS: A retrospective cohort study was conducted. Data were gathered from adults diagnosed and treated for GA at Fundación Valle del Lili (FVL), between 2000 and 2014, from the hospital’s own cancer registry and crossed with Cali’s Cancer Registry. Additional data were obtained directly from clinical records, pathology reports and the clinical laboratory. Patients younger than 18 years and those for whom limited information was available in the medical history were excluded. A survival analysis was conducted using Kaplan-Meier method. RESULTS: A total of 500 patients met eligibility criteria. Median age was 64 years (IQR: 54-74 years), 39.8% were female, 22.2% were at an early stage, 32.2% had a locally advanced disease, and 29% a metastatic disease, 69% had intestinal subtype, 48.6% had a positive H. pylori test, 85.2% had a distal lesion, 62% underwent gastrectomy, 60.6% lymphadenectomy, and 40.6% received chemotherapy. Survival at 5 years for all cases was 39.9% (CI 95% 35.3-44.5). Survival decreased over time in all groups and was lower in age-groups <39 and 60-79 with either locally advanced or metastatic disease. Prognostic factors that were significant in the Cox proportional-hazards model were late stages of the tumor (locally advanced: HR=2.52; metastatic: HR=4.17), diffuse subtype (HR=1.40), gastrectomy (subtotal: HR=0.42; total: 0.44) and palliative chemotherapy (HR=0.61). CONCLUSIONS: The treatment of GA has changed in recent decades. GA survival was associated with clinical staging, diffuse subtype, gastrectomy and palliative chemotherapy. These findings must be interpreted in the context of a hospital-based study.
format Online
Article
Text
id pubmed-10028196
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100281962023-03-22 Gastric adenocarcinoma burden, trends and survival in Cali, Colombia: A retrospective cohort study Parra-Lara, Luis Gabriel Falla-Martínez, Juan Camilo Isaza-Pierotti, Daniel Francisco Mendoza-Urbano, Diana Marcela Tangua-Arias, Andrés R. Bravo, Juan Carlos Bravo, Luis Eduardo Zambrano, Ángela R. Front Oncol Oncology BACKGROUND: Gastric adenocarcinoma (GA) has changed in recent decades. Cancer estimates are often calculated from population-based cancer registries, which lack valuable information to guide decision-making (clinical outcomes). We describe the trends in clinical practice for GA using a hospital-based cancer registry over a timespan of 15 years. METHODS: A retrospective cohort study was conducted. Data were gathered from adults diagnosed and treated for GA at Fundación Valle del Lili (FVL), between 2000 and 2014, from the hospital’s own cancer registry and crossed with Cali’s Cancer Registry. Additional data were obtained directly from clinical records, pathology reports and the clinical laboratory. Patients younger than 18 years and those for whom limited information was available in the medical history were excluded. A survival analysis was conducted using Kaplan-Meier method. RESULTS: A total of 500 patients met eligibility criteria. Median age was 64 years (IQR: 54-74 years), 39.8% were female, 22.2% were at an early stage, 32.2% had a locally advanced disease, and 29% a metastatic disease, 69% had intestinal subtype, 48.6% had a positive H. pylori test, 85.2% had a distal lesion, 62% underwent gastrectomy, 60.6% lymphadenectomy, and 40.6% received chemotherapy. Survival at 5 years for all cases was 39.9% (CI 95% 35.3-44.5). Survival decreased over time in all groups and was lower in age-groups <39 and 60-79 with either locally advanced or metastatic disease. Prognostic factors that were significant in the Cox proportional-hazards model were late stages of the tumor (locally advanced: HR=2.52; metastatic: HR=4.17), diffuse subtype (HR=1.40), gastrectomy (subtotal: HR=0.42; total: 0.44) and palliative chemotherapy (HR=0.61). CONCLUSIONS: The treatment of GA has changed in recent decades. GA survival was associated with clinical staging, diffuse subtype, gastrectomy and palliative chemotherapy. These findings must be interpreted in the context of a hospital-based study. Frontiers Media S.A. 2023-03-07 /pmc/articles/PMC10028196/ /pubmed/36959805 http://dx.doi.org/10.3389/fonc.2023.1069369 Text en Copyright © 2023 Parra-Lara, Falla-Martínez, Isaza-Pierotti, Mendoza-Urbano, Tangua-Arias, Bravo, Bravo and Zambrano https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Parra-Lara, Luis Gabriel
Falla-Martínez, Juan Camilo
Isaza-Pierotti, Daniel Francisco
Mendoza-Urbano, Diana Marcela
Tangua-Arias, Andrés R.
Bravo, Juan Carlos
Bravo, Luis Eduardo
Zambrano, Ángela R.
Gastric adenocarcinoma burden, trends and survival in Cali, Colombia: A retrospective cohort study
title Gastric adenocarcinoma burden, trends and survival in Cali, Colombia: A retrospective cohort study
title_full Gastric adenocarcinoma burden, trends and survival in Cali, Colombia: A retrospective cohort study
title_fullStr Gastric adenocarcinoma burden, trends and survival in Cali, Colombia: A retrospective cohort study
title_full_unstemmed Gastric adenocarcinoma burden, trends and survival in Cali, Colombia: A retrospective cohort study
title_short Gastric adenocarcinoma burden, trends and survival in Cali, Colombia: A retrospective cohort study
title_sort gastric adenocarcinoma burden, trends and survival in cali, colombia: a retrospective cohort study
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028196/
https://www.ncbi.nlm.nih.gov/pubmed/36959805
http://dx.doi.org/10.3389/fonc.2023.1069369
work_keys_str_mv AT parralaraluisgabriel gastricadenocarcinomaburdentrendsandsurvivalincalicolombiaaretrospectivecohortstudy
AT fallamartinezjuancamilo gastricadenocarcinomaburdentrendsandsurvivalincalicolombiaaretrospectivecohortstudy
AT isazapierottidanielfrancisco gastricadenocarcinomaburdentrendsandsurvivalincalicolombiaaretrospectivecohortstudy
AT mendozaurbanodianamarcela gastricadenocarcinomaburdentrendsandsurvivalincalicolombiaaretrospectivecohortstudy
AT tanguaariasandresr gastricadenocarcinomaburdentrendsandsurvivalincalicolombiaaretrospectivecohortstudy
AT bravojuancarlos gastricadenocarcinomaburdentrendsandsurvivalincalicolombiaaretrospectivecohortstudy
AT bravoluiseduardo gastricadenocarcinomaburdentrendsandsurvivalincalicolombiaaretrospectivecohortstudy
AT zambranoangelar gastricadenocarcinomaburdentrendsandsurvivalincalicolombiaaretrospectivecohortstudy